structure of Quinazoline-2,6-diamine

Quinazoline-2,6-diamine

CAS No.: 882670-95-3
M. Wt: 160.17600
M. Fa: C8H8N4
InChI Key: JPQGNMIFCUOXTB-UHFFFAOYSA-N

Names and Identifiers of Quinazoline-2,6-diamine

CAS Number

882670-95-3

MDL Number

MFCD11040209

IUPAC Name

quinazoline-2,6-diamine

InChI

InChI=1S/C8H8N4/c9-6-1-2-7-5(3-6)4-11-8(10)12-7/h1-4H,9H2,(H2,10,11,12)

InChIKey

JPQGNMIFCUOXTB-UHFFFAOYSA-N

Canonical SMILES

C1=CC2=NC(=NC=C2C=C1N)N

UNSPSC Code

12352100

Physical and chemical properties of Quinazoline-2,6-diamine

Boiling Point

469.8ºC at 760 mmHg

Density

1.398g/cm3

Exact Mass

160.07500

Flash Point

269.2ºC

H Bond Acceptors

4

H Bond Donors

2

Index of Refraction

1.795

LogP

1.95660

Molecular Formula

C8H8N4

Molecular Weight

160.17600

PSA

77.82000

Safety Information of Quinazoline-2,6-diamine

Pictograms

Signal Word

 Warning

Safety Data Sheet
Supports customized editing of SDS information and downloading in PDF documents.

Applications of Quinazoline-2,6-diamine

Quinazoline-2,6-diamine has diverse applications across various fields:

  • Pharmaceutical Development: Its derivatives are being explored as potential therapeutic agents for bacterial infections and malaria.
  • Biochemical Research: The compound's ability to inhibit specific receptors such as vascular endothelial growth factor receptor and epidermal growth factor receptor makes it valuable in cancer research and treatment strategies.

Interaction Studies of Quinazoline-2,6-diamine

Quinazoline-2,6-diamine interacts with several biological targets:

  • Vascular Endothelial Growth Factor Receptor (VEGFR): Inhibition of this receptor disrupts angiogenesis, potentially starving tumors of necessary nutrients.
  • Epidermal Growth Factor Receptor (EGFR): Similar inhibition mechanisms apply here, affecting pathways crucial for cell proliferation and survival.

Biological Activity of Quinazoline-2,6-diamine

Quinazoline-2,6-diamine exhibits significant biological activity:

  • Antibacterial Properties: Research indicates that derivatives of quinazoline-2,6-diamine demonstrate potent antibacterial activity against multidrug-resistant strains of Staphylococcus aureus. These compounds have shown minimal toxicity and effective in vivo results, making them promising candidates for further development as antibacterial agents.
  • Antimalarial Activity: Studies have revealed that quinazoline derivatives possess antimalarial properties. For instance, a series of 6,7-dimethoxyquinazoline-2,4-diamines were synthesized and evaluated for their antimalarial activity, leading to the identification of compounds with significant efficacy against malaria.